Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) said they received a clinical trial approval for SKB445 from the Center for Drug Evaluation of the National Medical Products Administration on Jan. 20, according to a Monday filing with the Hong Kong Stock Exchange.
SKB445, a new antibody-drug conjugate (ADC) drug, shows promise in treating advanced solid tumors, demonstrating efficacy and safety in preclinical studies using OptiDCTM technology, the filing added.
The pharmaceutical company's shares were up by 1% in recent trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments